Overall, yes, although inclusion of ribavirin might be helpful in some patients with genotype 1a infection.
In recent phase III studies, the ABT-450/r-based regimen — a coformulated pill of ABT-450/r-ombitasvir (a ritonavir-boosted protease inhibitor plus an NS5A inhibitor; once daily) plus dasabuvir (a nonnucleoside polymerase inhibitor; 250 mg twice daily) and ribavirin (1000–1200 mg daily) — yielded response rates >95% in patients with hepatitis C virus (HCV) genotype 1 infection (NEJM JW Gastroenterol Apr 15 2014).
In two industry-funded, phase III trials, investigators assessed the efficacy of the ABT-450/r-based regimen with and without ribavirin. They randomized treatment-naive patients with genotype 1a HCV infection (419 patients) and genotype 1b HCV infection (305 patients) without cirrhosis to receive the regimen with ribavirin or placeb…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose